{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:59:45Z","timestamp":1777550385739,"version":"3.51.4"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI095437"],"award-info":[{"award-number":["AI095437"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq), Brazil","award":["480328\/2013-7"],"award-info":[{"award-number":["480328\/2013-7"]}]},{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq), Brazil","award":["407729\/2012-7"],"award-info":[{"award-number":["407729\/2012-7"]}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ)","award":["E-26\/010.001548\/2014"],"award-info":[{"award-number":["E-26\/010.001548\/2014"]}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ)","award":["E-26\/110.553\/2014"],"award-info":[{"award-number":["E-26\/110.553\/2014"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006132","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T13:37:49Z","timestamp":1514381869000},"page":"e0006132","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection"],"prefix":"10.1371","volume":"11","author":[{"given":"Claudia Magalhaes","family":"Calvet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3101-6606","authenticated-orcid":true,"given":"Diane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Lostracco-Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliane Batista","family":"de Mesquita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanderson","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Meuser-Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana Araujo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jair Lage","family":"Siqueira-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-5897","authenticated-orcid":true,"given":"William R.","family":"Roush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirian Claudia","family":"de Souza Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"McKerrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-8760","authenticated-orcid":true,"given":"Larissa M.","family":"Podust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"ref1","unstructured":"WHO. Chagas disease (American trypanosomiasis). In: Fact Sheet [Internet]. 2017 [cited 1 Jan 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en\/<\/ext-link>"},{"key":"ref2","first-page":"33","article-title":"Chagas disease in Latin America: an epidemiological update based on 2010 estimates","volume":"90","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"issue":"no:2","key":"ref3","first-page":"0074","article-title":"Nova tripanozomiaze humana","volume":"1","author":"C Chagas","year":"1909","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e3010","DOI":"10.1371\/journal.pntd.0003010","article-title":"Acute chagas disease: new global challenges for an old neglected disease","volume":"8","author":"D V Andrade","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/CMR.00005-11","article-title":"Trypanosoma cruzi and Chagas\u2019 disease in the United States","volume":"24","author":"C Bern","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1473-3099(13)70002-1","article-title":"Global economic burden of Chagas disease: a computational simulation model","volume":"13","author":"BY Lee","year":"2013","journal-title":"Lancet Infect Dis. Elsevier Ltd"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.gheart.2015.06.001","article-title":"The Burden of Chagas Disease","volume":"10","author":"JD Stanaway","year":"2015","journal-title":"Glob Heart"},{"issue":"Suppl","key":"ref8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0074-02762009000900006","article-title":"Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery","volume":"104","author":"JR Coura","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.idc.2012.03.002","article-title":"American trypanosomiasis (Chagas disease)","volume":"26","author":"A Rassi","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543784.2014.922952","article-title":"Therapeutical approaches under investigation for treatment of Chagas disease","volume":"23","author":"MT Bahia","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas Disease","volume":"156","author":"J Bermudez","year":"2015","journal-title":"Acta Trop"},{"key":"ref12","unstructured":"FDA USF&amp; DA. FDA approves first U.S. treatment for Chagas disease. In: Press Announcements [Internet]. 2017 [cited 5 Sep 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm573942.htm\" xlink:type=\"simple\">https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm573942.htm<\/ext-link>"},{"key":"ref13","unstructured":"CHEMO. U.S. FDA Approves Chemo Group\u2019s Benznidazole to Treat Children with Chagas Disease. In: Press Room [Internet]. 2017 [cited 9 May 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chemogroup.com\/us-fda-approves-chemo-groups-benznidazole-treat-children-chagas-disease\" xlink:type=\"simple\">http:\/\/www.chemogroup.com\/us-fda-approves-chemo-groups-benznidazole-treat-children-chagas-disease<\/ext-link>"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0036-46652002000100006","article-title":"Long term evaluation of etiological treatment of chagas disease with benznidazole","volume":"44","author":"JR Can\u00e7ado","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of Benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"C Morillo","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1590\/S0074-02762009000900042","article-title":"The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease","volume":"104","author":"JA Marin-Neto","year":"2009","journal-title":"Mem Inst Oswaldo Cruz Rio Janeiro"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.7326\/0003-4819-144-10-200605160-00006","article-title":"Long-term cardiac outcomes of treating chronic Chagas disease with Benznidazole versus no treatment","volume":"144","author":"R Viotti","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers the STOP-Chagas trial","volume":"69","author":"CA Morillo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref19","unstructured":"Riarte A. TRAENA: Placebo-controlled evaluation of impact of benznidazole treatment on long-term disease progression in adults with chronic Chagas disease. 62nd Annual Meeting of the American 460 Society of Tropical Medicine and Hygiene, November 13\u201317, 2013, Washington, DC. 2013."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.2174\/0929867322666150319120337","article-title":"Sterol biosynthesis pathway as an alternative for the anti-protozoan parasite chemotherapy","volume":"22","author":"ST de Macedo-Silva","year":"2015","journal-title":"Curr Med Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"11242","DOI":"10.1021\/cr5003134","article-title":"Drug strategies targeting CYP51 in neglected tropical diseases","volume":"114","author":"JY Choi","year":"2014","journal-title":"Chem Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijantimicag.2010.03.006","article-title":"A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease","volume":"36","author":"BP Olivieri","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4269\/ajtmh.2010.09-0620","article-title":"Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus","volume":"82","author":"M-J Pinazo","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/nature09224","article-title":"Chagas disease: pushing through the pipeline","volume":"465","author":"J Clayton","year":"2010","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"I Molina","year":"2014","journal-title":"N Engl J Med"},{"key":"ref26","unstructured":"Torrico F. E1224\u2013Results of proof of concept clinical trial in patients with chronic indeterminate Chagas disease. 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 13\u201317, 2013. 2013."},{"key":"ref27","unstructured":"DNDi. Drug trial for leading parasitic killer of the americas shows mixed results but provides new evidence for improved therapy. In: Press Release [Internet]. 2013 [cited 8 Feb 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.dndi.org\/2013\/media-centre\/press-releases\/e1224\/\" xlink:type=\"simple\">https:\/\/www.dndi.org\/2013\/media-centre\/press-releases\/e1224\/<\/ext-link>"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"E Chatelain","year":"2014","journal-title":"J Biomol Screen"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"JA Urbina","year":"2015","journal-title":"J Eukaryot Microbiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"CB Moraes","year":"2014","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1371\/journal.pntd.0000372","article-title":"Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit","volume":"3","author":"C-K Chen","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1128\/AAC.00281-10","article-title":"A nonazole CYP51 inhibitor cures Chagas\u2019 disease in a mouse model of acute infection","volume":"54","author":"PS Doyle","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/jm401067s","article-title":"Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-Chagas agents","volume":"56","author":"JY Choi","year":"2013","journal-title":"J Med Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/ml500010m","article-title":"R -configuration of 4-aminopyridyl-based inhibitors of CYP51 confers superior efficacy against Trypanosoma cruzi","volume":"5","author":"JY Choi","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1021\/jm500448u","article-title":"4-aminopyridyl-based CYP51 inhibitors as anti- Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency","volume":"57","author":"CM Calvet","year":"2014","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cbic.201402027","article-title":"Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives","volume":"15","author":"DF Vieira","year":"2014","journal-title":"ChemBioChem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"10162","DOI":"10.1021\/jm501568b","article-title":"Binding mode and potency of n indolyloxopyridinyl-4- aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51","volume":"57","author":"DF Vieira","year":"2014","journal-title":"J Med Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","article-title":"In vitro and in vivo experimental models for drug screening and development for Chagas disease","volume":"105","author":"AJ Romanha","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/cmi.12297","article-title":"Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection","volume":"16","author":"MD Lewis","year":"2014","journal-title":"Cell Microbiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/cmi.12584","article-title":"Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy","volume":"18","author":"MD Lewis","year":"2016","journal-title":"Cell Microbiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1128\/AAC.01294-15","article-title":"Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of Trypanosoma cruzi infection","volume":"59","author":"FH Guedes-Da-Silva","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s004360100376","article-title":"Modulation induced by estradiol in the acute phase of Trypanosoma cruzi infection in mice","volume":"87","author":"E de Souza","year":"2001","journal-title":"Parasitol Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1087057114552623","article-title":"A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging","volume":"20","author":"MD Lewis","year":"2014","journal-title":"J Biomol Screen"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"J Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jmoldx.2015.04.010","article-title":"Analytical validation of quantitative real-time PCR methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients","volume":"17","author":"JC Ram\u00edrez","year":"2015","journal-title":"J Mol Diagn. NIH Public Access"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging","volume":"59","author":"AF Francisco","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0166-6851(99)00129-2","article-title":"Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes","volume":"104","author":"A Liendo","year":"1999","journal-title":"Mol Biochem Parasitol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/bs.pmch.2014.12.001","article-title":"A new era for Chagas disease drug discovery?","volume":"54","author":"M Keenan","year":"2015","journal-title":"Prog Med Chem"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1128\/AAC.01714-15","article-title":"Drug susceptibility of genetically engineered Trypanosoma cruzi strains and sterile cure in animal models as a criterion for potential clinical efficacy of anti-T. cruzi drugs","volume":"59","author":"JA Urbina","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1371\/journal.pntd.0000651","article-title":"Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole","volume":"4","author":"C-K Chen","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"25582","DOI":"10.1074\/jbc.M110.133215","article-title":"Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi","volume":"285","author":"GI Lepesheva","year":"2010","journal-title":"J Biol Chem"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1074\/jbc.M109.067470","article-title":"Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections","volume":"285","author":"GI Lepesheva","year":"2010","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis","volume":"212","author":"GI Lepesheva","year":"2015","journal-title":"J Infect Dis"},{"key":"ref54","first-page":"1","article-title":"VNI cures acute and chronic experimental Chagas disease","author":"F Villalta","year":"2013","journal-title":"J Infect Dis"},{"key":"ref55","article-title":"Anti-trypanosomal activity of sterol 14\u03b1-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of Chagas disease induced by the Y strain <italic>Trypanosoma cruzi<\/italic>","author":"FH Guedes-da-Silva","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1038\/s41598-017-06275-z","article-title":"Therapeutic effects of sphingosine kinase inhibitor N,N- dimethylsphingosine (DMS) in experimental chronic Chagas disease cardiomyopathy","volume":"7","author":"J Fraga Vasconcelos","year":"2017","journal-title":"Sci Rep"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.49.4.1521-1528.2005","article-title":"Treatment with benznidazole during the chronic phase of experimental Chagas\u2019 disease decreases cardiac alterations","volume":"49","author":"S Garcia","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2174\/156652408785748004","article-title":"Chagas heart disease pathogenesis: one mechanism or many?","volume":"8","author":"KM Bonney","year":"2008","journal-title":"Curr Mol Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/0074-02760160334","article-title":"Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial","volume":"112","author":"A Rassi Jr","year":"2017","journal-title":"Mem Inst Oswaldo Cruz Rio Janeiro"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1086\/314889","article-title":"Parasite persistence correlates with disease severity and localization in chronic Chagas\u2019 disease","volume":"180","author":"L Zhang","year":"1999","journal-title":"J Infect Dis"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/pim.12107","article-title":"Immunoregulatory networks in human Chagas disease","volume":"36","author":"WO Dutra","year":"2014","journal-title":"Parasite Immunol. NIH Public Access"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1586\/14787210.5.4.717","article-title":"Etiological treatment of chronic Chagas disease: neglected \u201cevidence\u201d by evidence-based medicine","volume":"5","author":"R Viotti","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref63","first-page":"507","article-title":"The treatment of patients with HIV","volume":"107","author":"M Vogel","year":"2010","journal-title":"Dtsch Arztebl Int. Deutscher Arzte-Verlag GmbH"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies","volume":"373","author":"JAC Sterne","year":"2009","journal-title":"Lancet"},{"key":"ref65","article-title":"Recommendations for a public health approach","year":"2010"},{"key":"ref66","unstructured":"UNAIDS. Ending AIDS: progress towards the 90\u201390\u201390 targets | UNAIDS [Internet]. 2017 [cited 9 Aug 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/20170720_Global_AIDS_update_2017\" xlink:type=\"simple\">http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/20170720_Global_AIDS_update_2017<\/ext-link>"},{"key":"ref67","first-page":"533","article-title":"Participation of cell surface anionic sites in the interaction between Trypanosoma cruzi and macrophages","volume":"16","author":"MNSL Meirelles","year":"1984","journal-title":"J Submicrosc Cytol"},{"key":"ref68","first-page":"93","article-title":"Growth and differentiation in Trypanosoma cruzi. I\u2014Origin of metacyclic trypanosomes in liquid media","volume":"6","author":"EP Camargo","year":"1964","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0074-02761988000100016","article-title":"Biological aspects of the Dm 28c clone of Trypanosoma cruzi after metacyclogenesis in chemically defined media","author":"VT Contreras","year":"1988","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"key":"ref70","first-page":"389","article-title":"Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi","volume":"4","author":"Z Brener","year":"1962","journal-title":"Rev Inst Med Trop Sao Paulo"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:23:27Z","timestamp":1588969407000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006132"}},"subtitle":[],"editor":[{"given":"Igor C.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":70,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006132","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}